Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc1.1 | Early Career Oral Communications | SFEBES2015

A novel pharmacological approach to target LH and testosterone hypersecretion in women with polycystic ovary syndrome: a randomised, double-blind, placebo-controlled multi-centre randomised clinical trial of the neurokinin B receptor antagonist AZD4901

George Jyothis , Kakkar Rahul , Marshall Jayne , Scott Martin , Finkelman Richard , Ho Tony , McIntosh Stuart , Veldhuis Johannes , Skorupskaite Karolina , Anderson Richard , Webber Lorraine

LH hyper-secretion, driven by increased GnRH pulsatility, underpins excess testosterone secretion – a key clinical feature of PCOS.The kisspeptin-neurokinin B (NKB)-GnRH pathway has emerged as the pivotal regulator of reproduction. We hypothesised that pharmacologic blockade of NKB may address the central pathophysiology of LH hyper-secretion and hyperandrogenism in PCOS. We undertook a randomised, double blind, placebo-controlled multi-centre Phase...

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...

ea0065ec1.2 | Early Career Prize Lecture Translational | SFEBES2019

From bench to bedside and beyond: a novel therapy to improve wound healing in type 2 diabetes

Ajjan Ramzi , Hensor Elizabeth , Abbas Afroze , Galdo Francesco Del , Russell David , Shams Kave , Stewart Paul , Webber Lorraine , Pegg Lindsey , Freeman Adrian , Woods Janet , Eng Sookhoe , Taylor Angela , Arlt Wiebke , Tahrani Abd , Tiganescu Ana

The International Diabetes Federation estimates that type 2 diabetes mellitus (T2DM) will affect 642 million people by 2040. Chronically inflamed, hypoxic wounds are common in T2DM and represent a global unmet clinical need. Each year, diabetic foot ulcers cost the NHS £650 million and cause 1 in 200 UK deaths. This mortality is greater than colon, breast and prostate cancer combined. Glucocorticoids are used to treat a range of inflammatory conditions (e.g. asthma, eczem...

ea0049gp131 | Female Reproduction | ECE2017

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes affect 70% of menopausal women, can be long-lasting, and often severely impact on physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but not without risk. Neurokinin B is an important mediator of hot flushes in rodents and elevated hypothalamic expression occurs in menopausal women. Neurokinin B acts via the neurokinin 3 receptor. We therefore hypothesised that neurokinin 3 receptor antagonism could be a nove...